Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 3/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.56 |
| ▸ | PGR | P06401 | 3/20 | 0.54 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.51 |
| ▸ | ACLY | P53396 | 1/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.48 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.48 |
| ▸ | TUBB | P07437 | 1/20 | 0.48 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.48 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.48 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.48 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.48 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.48 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.48 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.48 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.48 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.48 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21708334 | 0.93 | STAT3 (0.57) | STAT3KEAP1NFE2L2PGRPTGES2 | |
| SCHEMBL21708292 | 0.89 | KEAP1 (0.60) | STAT3KEAP1NFE2L2PGRPTGES2 | |
| SCHEMBL21708311 | 0.88 | STAT3 (0.73) | STAT3KEAP1NFE2L2PGRTUBB4A | |
| SCHEMBL21708341 | 0.88 | STAT3 (0.73) | STAT3KEAP1NFE2L2PLAUTUBB4A | |
| SCHEMBL21708250 | 0.81 | ALDH1A1 (0.57) | STAT3ACLYTUBB4ATUBBTUBA3C | |
| SCHEMBL4735186 | 0.80 | LMNA (0.60) | KEAP1NFE2L2PGRAXLALDH1A1 | |
| SCHEMBL3098055 | 0.79 | AXL (0.52) | STAT3KEAP1NFE2L2PGRMAP2K4 | |
| SCHEMBL21708225 | 0.79 | STAT3 (0.60) | STAT3KEAP1NFE2L2PGRTUBB4A | |
| SCHEMBL21708219 | 0.78 | MAPT (0.54) | KEAP1NFE2L2PGRAXLALDH1A1 | |
| SCHEMBL8659936 | 0.77 | STAT3 (0.58) | STAT3KEAP1NFE2L2PGRPTGES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210107871-A1 | BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2021-04-15 | — | — | US | disclosed |
| US-20210107871-A1 | BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2021-04-15 | — | — | US | disclosed |
| EP-3611161-A1 | BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY | National University Corporation Hokkaido University (JP) | 2020-02-19 | — | — | EP | disclosed |
| EP-3611161-A1 | BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY | National University Corporation Hokkaido University (JP) | 2020-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107871-A1 | BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY | FLNA, FLNB, BRI3BP | STAT3 1257/4885KEAP1 3844/4885NFE2L2 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.